Full Generic Medicine Info
Dosage/Direction for Use

Type 2 diabetes mellitus
Adult: Initially, 25 mg tid. Increase if necessary after 4-8 wk to 50 mg tid and continue for 3 mth. Max: 100 mg tid.
Should be taken with food. Take w/ 1st bite of each main meal.
Patient w/ diabetic ketoacidosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or predisposition to this condition, chronic intestinal diseases associated w/ marked disorders of digestion or absorption and co-existing conditions that may deteriorate as a result of increased intestinal gas formation.
Special Precautions
Patient exposed to stress (e.g. fever, trauma, infection, surgery). Renal impairment. Pregnancy and lactation. Patient Counselling Adhere to diet and exercise regimen. Monitoring Parameters Periodic monitoring of blood glucose tests. Measure glycosylated Hb to monitor long term glycaemic control.
Adverse Reactions
Abdominal pain or discomfort, diarrhoea, flatulence, skin rash.
Drug Interactions
Concomitant use w/ insulin increases the risk of hypoglycaemia. Intestinal adsorbents (e.g. charcoal) and carbohydrate-splitting digestive enzyme supplements (e.g. amylase, pancreatin) may reduce glycaemic effects. May significantly reduce the bioavailability of ranitidine and propranolol.
Miglitol reversibly inhibits membrane-bound intestinal α-glucosidase enzymes which hydrolyse oligosaccharides and disaccharides to glucose and other monosaccharides in the small intestinal brush border. It delays carbohydrate breakdown, glucose absorption and reduces postprandial hyperglycaemia.
Absorption: Absorption from GI tract is saturable at high doses. Bioavailability: 50-70% (100 mg); 100% (25 mg). Time to peak plasma concentration: W/in 2-3 hr.
Distribution: It crosses the placenta and enters breast milk (small amounts). Volume of distribution: 0.18 L/kg. Plasma protein binding: <4%.
Metabolism: Not metabolised.
Excretion: Via urine (95%) as unchanged drug. Elimination half-life: Approx 2 hr.
Oral: Store at 25°C.
CIMS Class
Antidiabetic Agents
ATC Classification
A10BF02 - miglitol ; Belongs to the class of alpha glucosidase inhibitors. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by CIMS based on miglitol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in